Fibromyalgia: Diagnosis and management for the primary healthcare provider

Journal of Women's Health

Volumn 17, Issue 8, 2008, Pages 1379-1387

  Huynh, Christine N ^a   Yanni, Leanne M ^a   Morgan, Laura A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; GABAPENTIN; MILNACIPRAN; PARACETAMOL PLUS TRAMADOL; PAROXETINE; PREGABALIN; TRAMADOL; VENLAFAXINE;

ABNORMAL DREAMING; ACUPUNCTURE; ANOREXIA; ANXIETY DISORDER; APPETITE; ASTHENIA; BALNEOTHERAPY; BEHAVIOR THERAPY; BLURRED VISION; CHIROPRACTIC; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONFUSION; CONSTIPATION; DEPRESSION; DIAGNOSTIC TEST; DIARRHEA; DIZZINESS; DROWSINESS; DYSPEPSIA; EDEMA; EJACULATION DISORDER; ELECTROSTIMULATION THERAPY; EXERCISE; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HEADACHE; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HEART BLOCK; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; LETHARGY; MALAISE; MASSAGE; MENTAL HEALTH CARE; MUSCULOSKELETAL PAIN; NAUSEA; NERVOUSNESS; PERIPHERAL EDEMA; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; REVIEW; SEDATION; SENSITIVITY AND SPECIFICITY; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SWEATING; TASTE DISORDER; TREMOR; ULTRASOUND; URINE RETENTION; VOMITING; XEROSTOMIA; YAWNING;

ANTIDEPRESSIVE AGENTS; COMORBIDITY; EVIDENCE-BASED MEDICINE; EXERCISE; FIBROMYALGIA; HUMANS; PAIN; PRIMARY HEALTH CARE; SEROTONIN AGENTS;

EID: 52749091930     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0656     Document Type: Review

References (80)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
2. Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: The pathophysiology of fibromyalgia. Ann Intern Med 2007;146:726-734.
3. Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48:1420-1429.
4. Williams DA, Gracely RH. Biology and therapy of fibromyalgia. Functional magnetic resonance imaging findings in fibromyalgia. Arthritis Res Ther 2007;8:224-231.
5. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988;32:21-26.
6. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-1601.
7. Russell IJ, Fletcher EM, Vipraio GA, Alboukrek D, Michalek JE. Cerebrospinal fluid (CSF) substance P (SP) in fibromyalgia: Changes in CSF SP over time parallel changes in clinical activity. J Musculoskel Pain 1998;6:(suppl 2):77.
8. Houvenagel E, Forzy G, Leloire O, et al. Cerebrospinal fluid monoamines in primary fibromyalgia. Rev Rhum Mal Osteoartic 1990;57:21-23.
9. Adler GK, Geenen R. Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia. Rheum Dis Clin North Am 2005;31:187-202.
10. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172.
11. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-2395.
12. Goldenberg DL. Fibromyalgia syndrome a decade later: What have we learned? Arch Intern Med 1999;159:777-785.
13. Merskey H, Bogduk N. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms, 2nd ed. Editors: Merskey H and Bogduk N. Seattle, Washington: IASP Press, 1994.
14. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001;91:165-175.
15. Schaefer KM. Sleep disturbances linked to fibromyalgia. Holist Nurs Pract 2003;17:120-127.
16. Park DC, Glass JM, Minear M, Crofford LJ. Cognitive function in fibromyalgia patients. Arthritis Rheum 2001;44:2125-2133.
17. Huynh CN, Yanni LM, Morgan LA. Key practice points in the management of fibromyalgia. Am Fam Physician 2007;76:195-196.
18. Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am Vol 1996;22:285-303.
19. Marcus DA, Bernstein C, Rudy TE. Fibromyalgia and headache: An epidemiological study supporting migraine as part of the fibromyalgia syndrome. Clin Rheumatol 2005;24:595-601.
20. Rhodus NL, Fricton J, Carlson P, Messner R. Oral symptoms associated with fibromyalgia syndrome. J Rheumatol 2003;30:1841-1845.
21. Brand K, Littlejohn G, Kristjanson L, Wisniewski S, Hassard T. The fibromyalgia bladder index. Clin Rheumatol 2007;26:2097-2103.
22. Wallace DJ. Genitourinary manifestations of fibrositis: An increased association with the female urethral syndrome. J Rheumatol 1990;17:238-239.
23. Crofford LJ, Clauw DJ. Fibromyalgia: Where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum 2002;46:1136-1138.
24. Akkasilpa S, Goldman D, Magder LS, Petri M. Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. J Rheumatol 2005;32:48-50.
25. Okifuji A, Turk DC, Sinclair JD, Starz TW, Marcus DA. A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 1997;24:377-383.
26. White KP, Nielson WR, Harth M, Ostbye T, Speechley M. Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 2002;47:260-265.
27. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: Development and validation. J Rheumatol 1991;18:728-733.
28. Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol 2007;34:1415-1425.
29. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-113.
30. Antidepressants. In: McEvoy GK, ed. AHFS 2000 drug information, 42nd ed. Bethesda, MD: American Society of Health-System Pharmacists, 2000:2013-2018.
31. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum 2004;51:9-13.
32. Cymbalta (duloxetine) package insert. Indianapolis, IN: Eli Lilly & Company, 2005.
33. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15.
34. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-2984.
35. Effexor (venlafaxine) package insert. Philadelphia, PA: Wyeth Pharmaceuticals, 2006.
36. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37:1561-1565.
37. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14-17.
38. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005;32:1975-1985.
39. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE, Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-197.
40. Prozac (fluoxetine) Package Insert. Indianapolis, IN: Eli Lilly & Company, 2005.
41. Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 2007;120:448-454.
42. Treatment of fibromyalgia: A randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor. 1995. Available at ctr.gsk.co.uk/Summary/paroxetine/studylist.asp
43. Giordano N, Geraci S, Santacroce C, Mattii G, Battisti E, Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. Curr Therapeut Res 1999;60:696-702.
44. Lyrica (pregabalin) package insert. New York, NY: Pfizer Inc, 2005.
45. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-1273.
46. Arnold L, Russell I, Duan W. A 14-week, randomized, double-blind, placebo-controlled, monotherapy trial of pregabalin (BID) in patients with fibromyalgia syndrome (FMS). J Pain 2007;Suppl 8:S24.
47. Crofford L, Simpson S, Young J. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM) trial: A 6-month, double-blind, placebo-controlled trial of treatment with pregabalin. Pain 2008;136:419-431.
48. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-1344.
49. Ultram (tramadol) package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc., 2004.
50. Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: A controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998;18:13-19.
51. Russell IJ, Kamin M, Bennett RM. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2007;6:250-257.
52. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-545.
53. Mannerkorpi K, Burckhardt CS, Bjelle A. Physical performance characteristics of women with fibromyalgia. Arthritis Care Res 1994;7:123-129.
54. Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2007;4:CD003786.
55. Schachter CL, Busch AJ, Peloso PM, Sheppard MS. Effects of short versus long bouts of aerobic exercise in sedentary women with fibromyalgia: A randomized controlled trial. Phys Ther 2003;83:340-358.
56. van Santen M, Bolwijn P, Landewe R, et al. High or low intensity aerobic fitness training in fibromyalgia: Does it matter? J Rheumatol 2002;29:582-587.
57. Gowans SE, deHueck A. Pool exercise for individuals with fibromyalgia. Curr Opin Rheumatol 2007;19:168-173.
58. Jones KD, Burckhardt CS, Bennett JA. Motivational interviewing may encourage exercise in persons with fibromyalgia by enhancing self efficacy. Arthritis Rheum 2004;51:864-867.
59. Jones KD. Individualizing the exercise prescription for persons with fibromyalgia. Rheum Dis Clin of North Am 2002;28:419-436.
60. Bennett R, Nelson D. Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol 2006;2:416-424.
61. Williams DA. Psychological and behavioural therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:649-665.
62. Thieme K, Flor H, Turk DC. Psychological pain treatment in fibromyalgia syndrome: Efficacy of operant behavioral and cognitive behavioral treatments. Arthritis Res Ther 2006;8:R121-132.
63. Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:667-683.
64. Hadhazy VA, Ezzo J, Creamer P, Berman BM. Mind-body therapies for the treatment of fibromyalgia. A systematic review. J Rheumatol 2000;27:2911-2918.
65. Deluze C, Bosia L, Zirbs A, Chantraine A, Vischer TL. Electroacupuncture in fibromyalgia: Results of a controlled trial. BMJ 1992;305:1249-1252.
66. Assefi NP, Sherman KJ, Jacobsen C, Goldberg J, Smith WR, Buchwald D. A randomized clinical trial of acupuncture compared with sham acupuncture in fibromyalgia. Ann Intern Med. 2005;143:10-19.
67. Martin DP, Sletten CD, Williams BA, Berger IH. Improvement in fibromyalgia symptoms with acupuncture: Results of a randomized controlled trial. Mayo Clin Proc 2006;81:749-757.
68. Forseth KKO, Gran JT. Management of fibromyalgia: What are the best treatment choices? Drugs 2002;62:577-592.
69. Living with fibromyalgia, drugs approved to manage pain, 2007. Available at www.fda.gov/consumer/updates/fibromyalgia062107.html.
70. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: A meta-analysis. J Gen Intern Med 2000;15:659-666.
71. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-449.
72. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia - A randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35.
73. Bymaster FP, Zhang W, Carter PA, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002;160:353-361.
74. Farber L, Stratz TH, Bruckle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res 2001;21:1-13.
75. Spath M, Stratz T, Neeck G, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004;33:267-270.
76. Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007;8:633-638.
77. Senay EC, Adams EH, Geller A, et al. Physical dependence on ultram (tramadol hydrochloride): Both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003;69:233-241.
78. King T, Gardell LR, Wang R, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005;116:276-288.
79. Vera-Portocarrero LP, Zhang ET, King T, et al. Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain 2007;129:35-45.
80. Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J 2007;100:1028-1036.